Volume 28, No 5, May 2018

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 28 Issue 5, May 2018: 501-502

RESEARCH HIGHLIGHTS

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol ^1,2,3,4 and Guido Kroemer ^1,2,3,4,5,6

¹Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, Paris 75006, France; ²University of Paris Descartes, Sorbonne Paris Cité, Paris 75006, France; ³University of Pierre et Marie Curie, Paris 75006, France; ⁴Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif 94805,France; ⁵Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris 75015, France and ⁶Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm 17176, Sweden Correspondence: Guido Kroemer (kroemer@orange.fr)

A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently inCell Researchnow suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

10.1038/s41422-018-0031-9

FULL TEXT | PDF

Browse 1439